Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29841396 | 1.00 | CRBN (0.44) | CRBNDDB1DRD2HTR2AHTR1A | |
| SCHEMBL24735333 | 0.99 | CRBN (0.45) | CRBNDDB1DRD2HTR2AHTR1A | |
| SCHEMBL30963390 | 0.93 | CRBN (0.47) | CRBNDDB1DRD2HTR2AKMT2A | |
| SCHEMBL24735190 | 0.89 | KMT2A (0.48) | CRBNDRD2HTR2AHTR1AKMT2A | |
| SCHEMBL29841476 | 0.89 | KMT2A (0.48) | CRBNDRD2HTR2AHTR1AKMT2A | |
| SCHEMBL24735334 | 0.88 | KMT2A (0.48) | CRBNDRD2HTR2AKMT2AMEN1 | |
| SCHEMBL29841519 | 0.88 | KMT2A (0.48) | CRBNDRD2HTR2AKMT2AMEN1 | |
| SCHEMBL30963368 | 0.85 | DDB1 (0.42) | CRBNDDB1KMT2AMEN1NR3C1 | |
| SCHEMBL21409218 | 0.83 | TLR9 (0.51) | DRD2HTR2AKMT2AMEN1NR3C1 | |
| SCHEMBL24735127 | 0.83 | CRBN (0.47) | CRBNDDB1KMT2AMEN1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530222-B2 | Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders | BTK, LYN, SYK | CRBN 692/4885DDB1 1446/4885DRD2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.